ENTITY

Celltrion Inc (068270 KS)

532

Analysis

Health Care • South Korea

Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment

more

Refresh

Exchange Announcement • 30 Dec 2024 16:56

Decision on Acquisition of Treasury Stock

Exchange Announcement • 30 Dec 2024 16:56

Material Business Matters Related to Investment Decisions(FDA approval of IND for CTP44 (Darzalex biosimilar))

Exchange Announcement • 27 Dec 2024 09:53

Material Business Matters Related to Investment Decisions(CTP44(ë¤ìë ì¤ ë°ì´ì¤ìë°ë¬) ë¯¸êµ ìì 3ì ìíê³í ì¹ì¸)

Exchange Announcement • 27 Dec 2024 09:53

Material Business Matters Related to Investment Decisions(CTP44(???? ??????) ?? ?? 3? ???? ??)

Exchange Announcement • 24 Dec 2024 14:42

Material Business Matters Related to Investment Decisions(MFDS approval of BLA for Avtozma (CTP47, Actemra Biosimilar) IV)

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.4

x